HOT NEWS
Novartis
NovartisNovartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 97,000 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis RSS Channel

Filter     Display # 
# Article Title Hits
1 Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progression 549
2 Novartis set to sustain its leading global position in oncology 1424
3 Novartis receives approval in the European Union for Onbrez® Breezhaler® 742
4 Novartis receives regulatory approval in Germany for Celtura® 474
5 Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China 466
6 Novartis unveils Lab of Future concept to top European students at Biotechnology Leadership Camp (BioCamp) 612
7 Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer 1115
8 Novartis delivers strong operational performance in the first half of 2009 842
9 Once-yearly Aclasta® approved in EU to treat osteoporosis 2065
10 Sandoz to acquire EBEWE Pharma specialty generics business 1177
11 Glivec® approved in EU as first post-surgery therapy 1090
12 Novartis expects strong operational performance in 2009 669
13 Glivec® recommended for use in Europe as first post-surgery treatment for gastrointestinal stromal tumors (GIST) 1117
14 Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound 869
15 Novartis increases dividend by 25% based on strong 2008 results 896
16 Novartis launches Extavia®, the standard-of-care for relapsing forms of multiple sclerosis 984
17 Four innovative Novartis medicines approved in Japan 989
18 US Department of Health and Human Services awards Novartis USD 486 million contract 505
19 Novartis strengthens vaccine pipeline with agreement for novel CMV vaccines candidate 591
20 Sandoz receives positive EU opinion for biosimilar filgrastim 536
 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  Next 
  •  End 
  • »
Page 1 of 2
Bookmark and Share

Banner